Positive responses were also documented with BV-M in adults with previously treated cHL (overall response rate (ORR), 75%) [4] or systemic anaplastic large-cell lymphoma (sALCL), an aggressive PTCL subtype that universally expresses CD30 (ORR, 86%) [5]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.